Hennion & Walsh Asset Management Inc. Acquires 24,708 Shares of Celcuity Inc. (NASDAQ:CELC)

Hennion & Walsh Asset Management Inc. lifted its position in Celcuity Inc. (NASDAQ:CELC - Free Report) by 17.2% during the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 168,740 shares of the company's stock after purchasing an additional 24,708 shares during the quarter. Hennion & Walsh Asset Management Inc. owned 0.45% of Celcuity worth $1,706,000 at the end of the most recent reporting period.

Other large investors have also made changes to their positions in the company. Summit Investment Advisors Inc. lifted its position in Celcuity by 49.5% during the 4th quarter. Summit Investment Advisors Inc. now owns 3,421 shares of the company's stock worth $45,000 after buying an additional 1,132 shares in the last quarter. Aquatic Capital Management LLC acquired a new position in Celcuity during the 4th quarter worth about $50,000. GAMMA Investing LLC lifted its position in Celcuity by 1,237.4% during the 1st quarter. GAMMA Investing LLC now owns 1,324 shares of the company's stock worth $131,000 after buying an additional 1,225 shares in the last quarter. The Manufacturers Life Insurance Company acquired a new position in Celcuity during the 4th quarter worth about $142,000. Finally, Bleakley Financial Group LLC acquired a new position in Celcuity during the 4th quarter worth about $146,000. Institutional investors own 63.33% of the company's stock.

Celcuity Trading Up 10.8%

Shares of NASDAQ:CELC traded up $1.27 during mid-day trading on Friday, reaching $13.05. The stock had a trading volume of 188,195 shares, compared to its average volume of 291,638. The firm has a market cap of $494.15 million, a PE ratio of -5.00 and a beta of 0.37. The firm has a 50 day simple moving average of $10.39 and a two-hundred day simple moving average of $11.30. The company has a current ratio of 10.35, a quick ratio of 10.36 and a debt-to-equity ratio of 0.65. Celcuity Inc. has a twelve month low of $7.58 and a twelve month high of $19.77.

Celcuity (NASDAQ:CELC - Get Free Report) last announced its quarterly earnings results on Wednesday, May 14th. The company reported ($0.86) earnings per share for the quarter, beating analysts' consensus estimates of ($0.95) by $0.09. On average, research analysts predict that Celcuity Inc. will post -2.62 EPS for the current fiscal year.

Analyst Ratings Changes

Several brokerages recently issued reports on CELC. HC Wainwright reiterated a "buy" rating and set a $27.00 price target on shares of Celcuity in a research report on Monday, May 19th. Needham & Company LLC reiterated a "buy" rating and set a $29.00 price target on shares of Celcuity in a research report on Thursday, May 15th. Five investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus price target of $30.80.

Celcuity Company Profile

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.